These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3128511)

  • 1. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
    Sakamoto K; Yoshioka T; Shimizu J; Sato S; Nakajima H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
    Yoshioka T; Sato S; Ogata M; Sakamoto K; Sano H; Shima J; Yamamoto H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
    Kosugi A; Yoshioka T; Suda T; Sano H; Takahama Y; Fujiwara H; Hamaoka T
    J Leukoc Biol; 1987 Dec; 42(6):632-41. PubMed ID: 2960766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state.
    Sano H; Sato S; Shima J; Tada T; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Jul; 79(7):857-65. PubMed ID: 3139599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
    Yoshioka T; Fujiwara H; Takai Y; Ogata M; Shimizu J; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.
    Sakamoto K; Nakajima H; Shimizu J; Katagiri T; Kiyotaki C; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1988; 27(3):261-6. PubMed ID: 3141057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis.
    Sugihara S; Izumi Y; Yoshioka T; Yagi H; Tsujimura T; Tarutani O; Kohno Y; Murakami S; Hamaoka T; Fujiwara H
    J Immunol; 1988 Jul; 141(1):105-13. PubMed ID: 2967864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
    Takesue BY; Bartik MM; Mokyr MB
    Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
    Kern DE; Klarnet JP; Jensen MC; Greenberg PD
    J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
    Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
    Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function.
    Kruisbeek AM; Mond JJ; Fowlkes BJ; Carmen JA; Bridges S; Longo DL
    J Exp Med; 1985 May; 161(5):1029-47. PubMed ID: 3921649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship among function, phenotype, and specificity in primary allospecific T cell populations: identification of phenotypically identical but functionally distinct primary T cell subsets that differ in their recognition of MHC class I and class II allodeterminants.
    Golding H; Mizuochi T; McCarthy SA; Cleveland CA; Singer A
    J Immunol; 1987 Jan; 138(1):10-7. PubMed ID: 2946773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.